DN
Title | Published in | Access level | OA Policy | Year | Views | Downloads | |
---|---|---|---|---|---|---|---|
The Importance of MRI in the Early Diagnosis of Acute Invasive Fungal Rhinosinusitis | Diagnostics | 2025 | 91 | 10 | |||
Antifungal treatment duration in hematology patients with invasive mold infections : a real-life update | Open forum infectious diseases | 2024 | 39 | 24 | |||
Isavuconazole for the Treatment of Fungal Infections : A Real-life Experience From the Fungal Infection Network of Switzerland (FUNGINOS) | Open forum infectious diseases | 2024 | 25 | 39 | |||
Do infectious diseases after kidney retransplantation differ from those after first kidney transplantation ? | Open forum infectious diseases | 2024 | 70 | 24 | |||
Pitfalls in Valganciclovir Prophylaxis Dose Adjustment Based on Renal Function in Kidney Transplant Recipients | Transplant international | 2024 | 74 | 29 | |||
BK polyomavirus serotype-specific antibody responses in blood donors and kidney transplant recipients with and without new-onset BK polyomavirus-DNAemia : A Swiss Transplant Cohort Study | American journal of transplantation | 2024 | 11 | 11 | |||
Frequency and impact on renal transplant outcomes of urinary tract infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species | Frontiers in medicine | 2024 | 55 | 13 | |||
Pre-engraftment bacteremia after allogeneic hematopoietic cell transplantation without primary fluoroquinolone antibacterial prophylaxis | Transplant infectious disease | 2024 | 28 | 22 | |||
Epidemiology, outcomes and risk factors for recurrence of Clostridioides difficile infections following allogeneic hematopoietic cell transplantation : a longitudinal retrospective multicenter study | Bone marrow transplantation | 2024 | 43 | 13 | |||
Pitfalls in definitions on respiratory viruses and particularities of Adenovirus infection in hematopoietic cell transplantation patients : Recommendations from the EBMT practice harmonization and guidelines committee | Current research in translational medicine | 2024 | 17 | 4 | |||
Routine infectious disease consultation prior to an allogeneic hematopoietic cell transplant | Open forum infectious diseases | 2023 | 38 | 33 | |||
Comparing the Real-World Use of Isavuconazole to Other Anti-Fungal Therapy for Invasive Fungal Infections in Patients with and without Underlying Disparities : A Multi-Center Retrospective Study | Journal of Fungi | 2023 | 63 | 40 | |||
Vaccine-preventable infections among solid organ transplant recipients in Switzerland | JAMA network open | 2023 | 88 | 22 | |||
Revisiting cytomegalovirus serology in allogeneic hematopoietic cell transplant recipients | Clinical infectious diseases | 2023 | 73 | 37 | |||
Antifungal prophylaxis and pre-emptive therapy : when and how ? | Molecular aspects of medicine | 2023 | 51 | 17 | |||
Duration of antifungal treatment in mold infection : when is enough ? | Current opinion in infectious diseases | 2023 | 58 | 8 | |||
The present and future of blood virome in allogeneic hematopoietic cell transplant recipients | Current opinion in infectious diseases | 2023 | 65 | 15 | |||
Bloodstream infections in allogeneic haematopoietic cell recipients from the swiss transplant cohort study: trends of causative pathogens and resistance rates | Bone marrow transplantation | 2023 | 111 | 45 | |||
American Society for Transplantation and Cellular Therapy Series, #6 : Management of Invasive Candidiasis in Hematopoietic Cell Transplantation Recipients | Transplantation and cellular therapy | 2023 | 47 | 27 | |||
CMV Infection After Letermovir Primary Prophylaxis Discontinuation in Allogeneic Hematopoietic Cell Transplant Recipients | Open forum infectious diseases | 2023 | 81 | 21 | |||
Immunogenicity of High-Dose vs. MF59-adjuvanted vs. Standard Influenza Vaccine in Solid Organ Transplant Recipients : The STOP-FLU trial | Clinical infectious diseases | 2023 | 67 | 23 | |||
Immune monitoring-guided vs fixed duration of antiviral prophylaxis against cytomegalovirus in solid-organ transplant recipients. A Multicenter, Randomized Clinical Trial | Clinical infectious diseases | 2023 | 102 | 54 | |||
Invasive Aspergillosis and the Impact of Azole-resistance | Current fungal infection reports | 2023 | 45 | 22 | |||
Longitudinal Detection of Twenty DNA and RNA Viruses in Allogeneic Hematopoietic Stem Cell Transplant Recipients Plasma | Viruses | 2023 | 117 | 66 | |||
Bacteremia During the First Year After Solid Organ Transplantation : An Epidemiological Update | Open forum infectious diseases | 2023 | 85 | 36 | |||
Salvage Treatment of Refractory HSV Oral Lesions with Pritelivir in Allogeneic Hematopoietic Cell Transplant Recipients | Antimicrobial agents and chemotherapy | 2023 | 60 | 122 | |||
Hepatitis E Virus Infection Epidemiology in Recipients of Allogeneic Hematopoietic Cell Transplant | Open forum infectious diseases | 2023 | 40 | 30 | |||
Nouveautés dans la prise en charge de l’infection à cytomégalovirus chez les patients transplantés | Revue médicale suisse | 2023 | 53 | 8 | |||
Invasive Mold Infections in Allogeneic Hematopoietic Cell Transplant Recipients in 2020: Have We Made Enough Progress? | Open forum infectious diseases | 2022 | 242 | 132 | |||
Central nervous system infections in solid organ transplant recipients: Results from the Swiss Transplant Cohort Study | The Journal of infection | 2022 | 202 | 102 | |||
Atypical pulmonary phaeohyphomycosis due to Aureobasidium spp. - case report and brief literature review | Swiss medical weekly | 2022 | 150 | 33 | |||
Distribution of Aspergillus Species and Prevalence of Azole Resistance in Respiratory Samples From Swiss Tertiary Care Hospitals | Open forum infectious diseases | 2022 | 195 | 75 | |||
Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients | Antimicrobial agents and chemotherapy | 2022 | 60 | 80 | |||
Frequency and causes of antifungal treatment changes in allogeneic haematopoïetic cell transplant recipients with invasive mould infections | Mycoses | 2022 | 247 | 113 | |||
Impact of different urinary tract infection phenotypes within the first year post-transplant on renal allograft outcomes | American journal of transplantation | 2022 | 153 | 80 | |||
Letermovir for cytomegalovirus primary prophylaxis in a multiple abdominal/small bowel transplant recipient | Clinical transplantation | 2022 | 213 | 0 | |||
Epidemiology and outcomes of bone and joint infections in solid organ transplant recipients | American journal of transplantation | 2022 | 179 | 61 | |||
T cell receptor sequencing reveals reduced clonal breadth of T-cell responses against SARS-CoV-2 after natural infection and vaccination in allogeneic hematopoietic stem cell transplant recipients | Annals of oncology | 2022 | 143 | 43 | |||
When and how do we stop antifungal treatment for an invasive mould infection in allogeneic haematopoietic cell transplant recipients? | Mycoses | 2022 | 68 | 31 | |||
Surgical site infections after simultaneous pancreas kidney and pancreas transplantation in the Swiss Transplant Cohort Study | Journal of hospital infection | 2022 | 181 | 60 | |||
Epidemiology and outcomes of medically attended and microbiologically confirmed bacterial foodborne infections in solid organ transplant recipients | American journal of transplantation | 2022 | 165 | 67 | |||
Screening for Parasitic Infection and Tuberculosis in Immunosuppressed and Pre-Immunosuppressed Patients: An Observational Study | Tropical medicine and infectious disease | 2021 | 199 | 99 | |||
COVID-19-associated pulmonary aspergillosis (CAPA): how big a problem is it? | Clinical microbiology and infection | 2021 | 182 | 78 | |||
Progress and current challenges in the management of invasive fungal infections in hematologic malignancy patients and allogeneic hematopoietic cell transplant recipients | 2021 | 275 | 383 | ||||
Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study | Vaccines | 2021 | 168 | 157 | |||
Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study | American journal of transplantation | 2021 | 225 | 95 | |||
Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients | Immunity, inflammation and disease | 2021 | 286 | 80 | |||
Temporal trends, risk factors and outcomes of infections due to extended-spectrum β-lactamase producing Enterobacterales in Swiss solid organ transplant recipients between 2012 and 2018 | Antimicrobial resistance and infection control | 2021 | 313 | 74 | |||
Burden, epidemiology, and outcomes of microbiologically confirmed respiratory viral infections in solid organ transplant recipients: a nationwide, multi-season prospective cohort study | American journal of transplantation | 2021 | 116 | 81 | |||
Clinical considerations of isavuconazole administration in high-risk hematological patients: a single-center 5-year experience | Mycopathologia | 2021 | 202 | 109 | |||
Clinical considerations on posaconazole administration and therapeutic drug monitoring in allogeneic hematopoietic cell transplant recipients | Medical mycology | 2021 | 279 | 1 | |||
Invasive aspergillosis in solid organ transplant patients: diagnosis, prophylaxis, treatment, and assessment of response | BMC infectious diseases | 2021 | 120 | 110 | |||
Differences between infectious disease events in first liver transplant versus retransplantation in the Swiss Transplant Cohort Study | Liver transplantation | 2021 | 110 | 0 | |||
Editorial: Transplant infectious disease landscape in the COVID19-Era | Current opinion in infectious diseases | 2021 | 155 | 0 | |||
The EHA research roadmap: infections in hematology | HemaSphere | 2021 | 164 | 73 | |||
Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir | Antimicrobial agents and chemotherapy | 2021 | 193 | 283 | |||
Trends of the Epidemiology of Candidemia in Switzerland: A 15-Year FUNGINOS Survey | Open forum infectious diseases | 2021 | 54 | 49 | |||
Real-life considerations on antifungal treatment combinations for the management of invasive mold infections after allogeneic cell transplantation | Journal of Fungi | 2021 | 151 | 98 | |||
Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study | The journal of antimicrobial chemotherapy | 2021 | 169 | 0 | |||
Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients | Medical mycology | 2021 | 136 | 0 | |||
Invasive aspergillosis due to Aspergillus section Usti: a multicenter retrospective study | Clinical Infectious Diseases | 2020 | 196 | 478 | |||
Risk factors for candidemia: a prospective matched case-control study | Critical Care | 2020 | 302 | 100 | |||
Response to "Missed diagnosis and misdiagnosis of infectious diseases in hematopoietic cell transplant recipients: an autopsy study" | Blood advances | 2020 | 164 | 38 | |||
Emerging echinocandin-resistant Candida albicans and glabrata in Switzerland | Infection | 2020 | 202 | 95 | |||
First experience of SARS-CoV-2 infections in solid organ transplant recipients in the Swiss Transplant Cohort Study | American Journal of Transplantation | 2020 | 254 | 98 | |||
Intracellular Pathogen in the Cerebrospinal Fluid of an Allogeneic Hematopoietic Cell Transplant Recipient With Graft-Versus-Host Disease and Brain Lesions | Clinical infectious diseases | 2020 | 231 | 0 | |||
Reasons for voriconazole prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients: A real-life paradigm | Medical Mycology | 2020 | 172 | 234 | |||
Optimal treatment duration of pseudomonas aeruginosa infections in allogeneic hematopoietic cell transplant recipients | Open Forum Infectious Diseases | 2020 | 426 | 109 | |||
First case of Cryptococcus gattii multilobar pneumonia in Switzerland and associated challenges | Swiss Medical Weekly | 2020 | 349 | 119 | |||
Combination treatment with letermovir and ganciclovir for maintenance therapy of multidrug-resistant CMV infection in a liver transplant recipient | Transplantation | 2020 | 311 | 1 | |||
Microbiologically documented infections after adult allogeneic hematopoietic cell transplantation: A 5-year analysis within the Swiss Transplant Cohort study | Transplant Infectious Disease | 2020 | 353 | 2 | |||
Prophylaxie antimicrobienne et approches thérapeutiques empiriques et préemptives pour la prévention des infections chez les receveurs de greffe allogénique de cellules hématopoïétiques | 2020 | 397 | 178 | ||||
Infectiologie sur mesure - 1. Immunogénétique des maladies infectieuses : premiers pas | Revue médicale suisse | 2019 | 232 | 3 | |||
National point prevalence survey on healthcare-associated infections in acute care hospitals, Switzerland, 2017 | Euro Surveillance | 2019 | 327 | 125 | |||
Antimicrobial prophylaxis and preemptive approaches for the prevention of infections in the stem cell transplant recipient, with analogies to the hematologic malignancy patient | Infectious disease clinics of North America | 2019 | 136 | 146 | |||
Epidemiology, risk factors and outcomes of invasive aspergillosis in solid organ transplant recipients in the Swiss Transplant Cohort Study | Transplant Infectious Disease | 2018 | 484 | 0 | |||
Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy | Haematologica | 2018 | 220 | 126 | |||
Accuracy of Sensititre YeastOne echinocandins epidemiological cut-off values for identification of FKS mutant Candida albicans and Candida glabrata: a ten year national survey of the Fungal Infection Network of Switzerland (FUNGINOS) | Clinical Microbiology and Infection | 2018 | 249 | 176 | |||
Efficacy of brincidofovir as prophylaxis against HSV and VZV in hematopoietic cell transplant recipients | Transplant Infectious Disease | 2018 | 260 | 93 | |||
Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study | Transplant Infectious Disease | 2018 | 430 | 0 | |||
Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort | Transplant Infectious Disease | 2018 | 353 | 1 | |||
First case of Candida auris in Switzerland: discussion about preventive strategies | Swiss Medical Weekly | 2018 | 462 | 197 |